SHR-1819 / Jiangsu Hengrui Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-1819 / Jiangsu Hengrui Pharma
NCT06468956: Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Not yet recruiting
3
650
RoW
SHR-1819, Placebo
Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Atopic Dermatitis
04/25
03/26

Download Options